These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 17366593)

  • 1. The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
    Kantarjian H; Giles F; List A; Lyons R; Sekeres MA; Pierce S; Deuson R; Leveque J
    Cancer; 2007 May; 109(9):1705-14. PubMed ID: 17366593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome.
    Gonzalez-Porras JR; Cordoba I; Such E; Nomdedeu B; Vallespi T; Carbonell F; Luño E; Ardanaz M; Ramos F; Pedro C; Gomez V; de Paz R; Sanchez-Barba M; Sanz GF; Del Cañizo AC;
    Cancer; 2011 Dec; 117(24):5529-37. PubMed ID: 21638279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet associated IgG may be related with thrombocytopenia in patients with myelodysplastic syndromes.
    Gilli SC; de Souza Medina S; de Castro V; Fernandes LG; Saad ST
    Leuk Res; 2012 May; 36(5):554-9. PubMed ID: 22129476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporating new modalities into guidelines. Topotecan for myelodysplastic syndromes.
    Estey EH
    Oncology (Williston Park); 1998 Nov; 12(11A):81-6. PubMed ID: 10028504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome.
    Chan G; DiVenuti G; Miller K
    Am J Hematol; 2002 Nov; 71(3):166-71. PubMed ID: 12410570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes.
    Neukirchen J; Blum S; Kuendgen A; Strupp C; Aivado M; Haas R; Aul C; Gattermann N; Germing U
    Eur J Haematol; 2009 Nov; 83(5):477-82. PubMed ID: 19548919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
    Kao JM; McMillan A; Greenberg PL
    Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolution of hematopoietic SCT in myelodysplastic syndrome.
    Kindwall-Keller T; Isola LM
    Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelodysplasia: when to treat and how.
    Larson RA
    Best Pract Res Clin Haematol; 2006; 19(2):293-300. PubMed ID: 16516126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
    Dreyfus F
    Blood Rev; 2008 Dec; 22 Suppl 2():S29-34. PubMed ID: 19059054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A preliminary study of prognostic value of thrombocytopenia in patients with primary myelodysplastic syndromes].
    Chen YD; Xu ZF; Cui R; Wang JY; Zhang TJ; Fang LW; Zhang HL; Qin TJ; Zhang Y; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):532-5. PubMed ID: 22967412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet function in the myelodysplastic syndromes.
    Mittelman M; Zeidman A
    Int J Hematol; 2000 Feb; 71(2):95-8. PubMed ID: 10745619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoietic growth factors in the treatment of acquired bone marrow failure states.
    Marsh JC; Ganser A; Stadler M
    Semin Hematol; 2007 Jul; 44(3):138-47. PubMed ID: 17631178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the prevalence of myelodysplastic syndromes in patients with unexplained cytopenias: a retrospective study of 322 bone marrows.
    Buckstein R; Jang K; Friedlich J; Zhang L; Reis M; Chesney A; Wells RA
    Leuk Res; 2009 Oct; 33(10):1313-8. PubMed ID: 19282029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory drugs in the treatment of myelodysplastic syndromes.
    Ortega J; List A
    Curr Opin Oncol; 2007 Nov; 19(6):656-9. PubMed ID: 17906467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.
    Al Ameri A; Jabbour E; Garcia-Manero G; O'Brien S; Faderl S; Ravandi F; Shan J; Pierce S; Cortes J; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):237-41. PubMed ID: 21575929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombopoiesis-stimulating agents and myelodysplastic syndromes.
    Brierley CK; Steensma DP
    Br J Haematol; 2015 May; 169(3):309-23. PubMed ID: 25659186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Significance of Platelet Recovery in Myelodysplastic Syndromes With Severe Thrombocytopenia.
    Tang Y; Zhang X; Han S; Chu T; Qi J; Wang H; Tang X; Qiu H; Fu C; Ruan C; Wu D; Han Y
    Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):217S-222S. PubMed ID: 30296835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombocytopenia in myelodysplastic syndromes and myelofibrosis.
    Boruchov AM
    Semin Hematol; 2009 Jan; 46(1 Suppl 2):S37-43. PubMed ID: 19245933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.